



Attorney's Docket No. 5470-130DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

AUG 06 2001
PATENT

TECH CENTER 1600/2900

In re: French et al.

Serial No.: 09/497,822

Filed: February 3, 2000

For: *ANDROGEN RECEPTOR PROTEINS RECOMBINANT DNA MOLECULES
AND CODING FOR SUCH AND USE OF SUCH COMPOSITIONS*

Examiner: M. Pak

Group Art Unit: 1646

Commissioner for Patents
Washington, DC 20231

Date: July 31, 2001

SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Please enter the following amendment prior to examination of the above-referenced application.

In the Drawings:

Please amend the drawings as follow.

Please cancel Figure 7.

Please rename Figure 8 and Figure 9 as originally filed as Figure 7 and Figure 8, respectively.

In the Specification:

Please replace the paragraph beginning at page 1, line 17, and ending at page 1, line 28, with the following rewritten paragraph:

B1 -- The naturally occurring androgenic hormones, testosterone and its 5 α -reduced metabolite, dihydrotestosterone, are synthesized by the Leydig cells of the testes and circulate throughout the body where they diffuse into cells and bind to the androgen receptor protein ("AR"). Androgens, acting through their receptor, stimulate development of the male genitalia and accessory sex glands in the fetus, virilization and growth in the pubertal male, and maintenance of male virility and reproductive function in the adult. The androgen receptor, together with other steroid hormone receptors constitute a family of trans-acting transcriptional regulatory